Clinical Trials Logo

Stomach Neoplasms clinical trials

View clinical trials related to Stomach Neoplasms.

Filter by:

NCT ID: NCT02852252 Completed - Gastric Cancer Clinical Trials

Solid Tumor Cancer Surgery With or Without Intraoperative Imaging: A Registry

Start date: July 2016
Phase:
Study type: Observational [Patient Registry]

The study objective is to collect prospective data on cancer patients who undergo surgery and intraoperative imaging. The registry will include (but not limited to) cancer type, stage, intraoperative challenges to the surgeon, usage and results of intraoperative imaging, and recurrence surveillance.

NCT ID: NCT02852096 Recruiting - Gastric Cancer Clinical Trials

Assessing Her2/Neu Expression in Gastric Cancer With Dual or Multiple Tumor Tissue Paraffin Blocks

Start date: November 2015
Phase: N/A
Study type: Interventional

One paraffin block is routinely used for Human Epidermal Growth Factor Receptor 2 (Her2/neu) immunohistochemistry (IHC) assessment. Here, investigators investigated if picking two or multiple paraffin blocks for Her2/neu evaluation is an economical, efficient and practical method, which may reduce false-negativity of Her2/neu IHC assessment due to intratumoral heterogeneity.

NCT ID: NCT02848066 Completed - Gastric Cancer Clinical Trials

Glycans Bound to Serum Haptoglobin: a Novel Gastric Cancer Tumor Biomarker

Start date: July 2015
Phase:
Study type: Observational

The purpose of this study is to evaluate sensitivity and specificity of newly defined tumor biomarker with gastric cancer pts and cancer-free healthy volunteers.

NCT ID: NCT02845986 Active, not recruiting - Stomach Neoplasms Clinical Trials

Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer

CLASS-04
Start date: September 1, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore the safety and feasibility of the Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for patients with locally advanced upper third gastric adenocarcinoma(cT2-4a, N-/+, M0).

NCT ID: NCT02845908 Completed - Clinical trials for Malignant Neoplasm of Stomach Stage IV

POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC

Start date: November 2015
Phase: Phase 2
Study type: Interventional

The aim of this study was to compare the efficacy and safety of POF, FOLFOX, and FOLFOX plus paclitaxel(ip) as first-line treatment in AGC a phase II clinical trial.

NCT ID: NCT02845479 Completed - Lung Neoplasms Clinical Trials

The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial- Stage I

POISE
Start date: December 7, 2018
Phase: Phase 3
Study type: Interventional

Stage I of the Thoracic-POISE study will pilot-test a broad-based, multi-agent integrative care intervention delivered by naturopathic doctors in conjunction with standard surgical and oncologic care of people with thoracic cancer.

NCT ID: NCT02843412 Not yet recruiting - Clinical trials for Gastric Cancer Surgical Specimens,18-80 Years Old, at Least Two Tumor Tissue Blocks

The Clinical Study of Assessing HER-2 Expression in Gastric Cancer With Extra Tumor Tissue Paraffin Blocks Using Immunohistochemistry

Start date: August 2016
Phase: N/A
Study type: Observational

Background: Gastric cancer (GC) is major global health concern and the second leading cause of cancer deaths worldwide. Amplification of Her2/neu gene and/or overexpression of the Her2/neu protein have been observed in GC. Trastuzumab (Herceptin™) is an anti-Her2/neu antibody, which has been successfully applied in GC. However, the intratumoral heterogeneity of Her2/neu overexpression and amplification in GC should be noticed. The investigators investigated the significance of evaluating Her2/neu expression in different paraffin blocks of tumor tissue in GC. Methods: 2000 GC patients from ten centers, patients were divided into a cohort using one tumor tissue paraffin block (cohort 1, n=1000) and a cohort using dual tumor tissue paraffin blocks (cohort 2, n=1000) when evaluating Her2/neu expression status by immunohistochemistry (IHC). In cohort 2, the investigators combined the results from two different paraffin blocks and used the higher one as the final score.

NCT ID: NCT02839954 Recruiting - Clinical trials for Non-small Cell Lung Cancer

CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor

Start date: July 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.

NCT ID: NCT02837874 Recruiting - Stomach Neoplasms Clinical Trials

Comparisons Between Isoperistaltic and Antiperistaltic Gastrojejunostomy in Laparoscopic Distal Gastrectomy

Start date: March 2016
Phase: N/A
Study type: Interventional

Billroth-II (gastrojejunostomy) is one of major option after gastrectomy for gastric cancer. The investigators hypothesized that isoperistaltic anastomosis lead to higher incidence of dumping syndrome but antiperistaltic (anisoperistaltic) anastomosis have relevance to gastric stasis or obstruction. The investigators will assess complications, dumping syndrome and quality of life between isoperistaltic and antiperistaltic after distal gastrectomy for gastric cancer.

NCT ID: NCT02833363 Recruiting - Gastric Cancer Clinical Trials

Difference of Gastric Microbiota in the Process of Correa's Model.

Start date: July 2016
Phase: Phase 4
Study type: Observational

Helicobater pylori plays an important role in the development of gastric cancer. Eradication therapy can reducing the morbidity of gastric cancer, but can't totally prevent it especially when atrophy and more serious precancerous lesions already happened. Prior studies found the gastric bacterial difference among gastritis, intestinal metaplasia and gastric cancer. However, they didn't reach an agreement. Correa's model is widely accepted in the development of gastric cancer. The pathological change makes a more suitable environment for bacteria to overgrowth. This study are designed to analyze the gastric microbial difference of non-atrophic gastritis, atrophic gastritis, intestinal metaplasia, intraepithelial neoplasia and gastric cancer.